New patent application - on serum TK1 levels for prediction of cancer relapse

AroCell AB announced today that a patent application has been filed in the US relating to the measurement of thymidine kinase 1 (TK1), and in particular to the prediction of cancer relapse based on measured serum TK1 levels.

The patent application is based on a study in patients with diffuse large B-cell lymphoma (DLBCL). The study showed that the TK1 concentrations in these patients could predict cancer relapse.

"This patent application broadens our area of use of TK1 in oncology. We are happy to be able to continue to develop our portfolio and expand the usability of AroCell TK 210 ELISA in oncology" says Anders Hultman, CEO AroCell.

Contacts

Anders Hultman, CEO
Phone: +46(0)18 50 30 20
E-mail: anders.hultman@arocell.com

About AroCell

AroCell AB (publ) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure Thymidine Kinase 1 (TK1) protein concentrations in a blood sample. The TK 210 ELISA test provides valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of tumor disease during the monitoring of the disease. AroCell (AROC) is listed at Nasdaq First North Growth Market with Redeye AB as Certified Adviser: Certifiedadviser@redeye.se, +46 (0)8 121 576 90. For more information; www.arocell.com

Attachments

New patent application - on serum TK1 levels for prediction of cancer relapse